<DOC>
	<DOCNO>NCT02553317</DOCNO>
	<brief_summary>The study phase III , double blind , placebo-controlled , randomize study evaluate efficacy safety caplacizumab rapidly restore normal platelet count measure prevention microvascular thrombosis</brief_summary>
	<brief_title>Phase III Trial With Caplacizumab Patients With Acquired Thrombotic Thrombocytopenic Purpura</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<criteria>1 . Adult male female ≥ 18 year age time sign informed consent form ( ICF ) . 2 . Clinical diagnosis acquire TTP ( initial recurrent ) , include thrombocytopenia microscopic evidence red blood cell fragmentation ( e.g. , schistocytes ) . 3 . Requires initiation daily PE treatment receive 1 PE treatment prior randomization 4 . Others define protocol 1 . Platelet count ≥100×10E9/L . 2 . Serum creatinine level &gt; 200 µmol/L case platelet count &gt; 30×10E9/L 3 . Known cause thrombocytopenia 4 . Congenital TTP ( know time study entry ) . 5 . Pregnancy breastfeed . 6 . Subjects previously enrol clinical study caplacizumab receive caplacizumab assign treatment arm unknown 6 . Others define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>